FDA Priority Review Status Refusals Show Need For Clinical Outcomes Data
This article was originally published in Pharmaceutical Approvals Monthly
Sponsors who plan to seek priority review status need to show a superior effect on clinical outcomes, an examination of priority review requests rejected by FDA suggests
You may also be interested in...
FDA’s determination that The Medicines Company’s Cleviprex did not actually show a significant benefit over other intravenous antihypertensives caused the agency to make a rare move, and downgrade the application from a priority to a standard review.
The "curious" failure of subjective secondary endpoints to agree with the efficacy of Takeda’s Rozerem on objective sleep measures contributed to a debate at FDA over the clinical significance of the insomnia therapy.